These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31591672)

  • 1. Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.
    Wu EQ; Zhou ZY; Xie J; Metallo C; Thokala P
    Pharmacoeconomics; 2019 Nov; 37(11):1349-1354. PubMed ID: 31591672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States.
    Carlson JJ; Walton SM; Basu A; Chapman RH; Campbell JD; McQueen RB; Pearson SD; Touchette DR; Veenstra D; Whittington MD; Ollendorf DA
    Pharmacoeconomics; 2019 Nov; 37(11):1321-1327. PubMed ID: 31485925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility.
    Büyükkaramikli NC; Rutten-van Mölken MPMH; Severens JL; Al M
    Pharmacoeconomics; 2019 Nov; 37(11):1391-1408. PubMed ID: 31705406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Health Economics' and the evolution of economic evaluation of health technologies.
    Hutton J
    Health Econ; 2012 Jan; 21(1):13-8. PubMed ID: 22147623
    [No Abstract]   [Full Text] [Related]  

  • 5. Model Structuring for Economic Evaluations of New Health Technologies.
    Haji Ali Afzali H; Bojke L; Karnon J
    Pharmacoeconomics; 2018 Nov; 36(11):1309-1319. PubMed ID: 30030816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling".
    Zawadzki NK; Hay JW
    Int J Health Policy Manag; 2020 Aug; 9(8):352-355. PubMed ID: 32613807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages and disadvantages of discrete-event simulation for health economic analyses.
    Caro JJ; Möller J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):327-9. PubMed ID: 26967022
    [No Abstract]   [Full Text] [Related]  

  • 8. Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.
    Frederix GW; Haji Ali Afzali H; Dasbach EJ; Ward RL
    Pharmacoeconomics; 2015 Aug; 33(8):777-81. PubMed ID: 25827099
    [No Abstract]   [Full Text] [Related]  

  • 9. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project.
    Jansen JP; Incerti D; Linthicum MT
    Pharmacoeconomics; 2019 Nov; 37(11):1313-1320. PubMed ID: 31392665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four Aspects Affecting Health Economic Decision Models and Their Validation.
    Feenstra T; Corro-Ramos I; Hamerlijnck D; van Voorn G; Ghabri S
    Pharmacoeconomics; 2022 Mar; 40(3):241-248. PubMed ID: 34913142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field.
    Grieve R; Hutton J; Green C
    Health Policy; 2003 Jun; 64(3):311-24. PubMed ID: 12745170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Discrete-event simulation models in the economic evaluation of health technologies and health products].
    Rodríguez Barrios JM; Serrano D; Monleón T; Caro J
    Gac Sanit; 2008; 22(2):151-61. PubMed ID: 18420015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Value of Medicines: A Crucial but Vague Concept.
    Antoñanzas F; Terkola R; Postma M
    Pharmacoeconomics; 2016 Dec; 34(12):1227-1239. PubMed ID: 27444306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transparency in Decision Modelling: What, Why, Who and How?
    Sampson CJ; Arnold R; Bryan S; Clarke P; Ekins S; Hatswell A; Hawkins N; Langham S; Marshall D; Sadatsafavi M; Sullivan W; Wilson ECF; Wrightson T
    Pharmacoeconomics; 2019 Nov; 37(11):1355-1369. PubMed ID: 31240636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health technology assessment.
    Hailey D
    Singapore Med J; 2006 Mar; 47(3):187-92; quiz 193. PubMed ID: 16518551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Economic Model Transparency Improve Provider Interpretation of Cost-Effectiveness Analysis? A Response.
    Cohen JT; Wong JB
    Med Care; 2017 Nov; 55(11):912-914. PubMed ID: 29028754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches for economic evaluations of health care technologies.
    Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
    Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
    Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health technology assessment in Brazil - an international perspective.
    Lima SGG; Brito C; Andrade CJC
    Cien Saude Colet; 2019 May; 24(5):1709-1722. PubMed ID: 31166506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.